Highlights
- •We report a case of multiple dissections after Rituximab.
- •Accountability of Rituximab cannot be excluded.
- •The cytokine release after Rituximab infusion could be a trigger.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Rituximab induced myocardial infarction: A fatal drug reaction.Journal of Cancer Research and Therapeutics. 2011; 7: 346
- Spontaneous multiple cervical artery dissections after alemtuzumab.Multiple Sclerosis Journal. 2019 May 9; (135245851982866)
- Coming off cannabis: a cognitive and magnetic resonance imaging study in patients with multiple sclerosis.Brain. 2019 Sep 1; 142: 2800-2812
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.New England Journal of Medicine. 2017 Jan 19; 376: 209-220
- Infusion-related reactions to rituximab: frequency, mechanisms and predictors.Expert Review of Clinical Immunology. 2019 Apr 3; 15: 383-389
Article info
Publication history
Published online: April 16, 2020
Accepted:
April 5,
2020
Received in revised form:
April 3,
2020
Received:
January 3,
2020
Identification
Copyright
© 2020 Elsevier B.V. All rights reserved.
